Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 01, 2006 (Vol. 26, No. 17)

myProteome.com-The Proteomics IT Blog

URL:www.myproteome.com
  • Useful links
  • News not updated
If there is a biotech topic crying out for a good blog, it is proteomics. Aiming to be at the hub of this new field, myProteome.com brings to the plate a format like that of Mass Spectrometry Blog, mixing news with relevant links. In the case of myProteome.com, the links shine more brightly than the news. In fact, the news coverage seemed to be at least average but then stopped in January, 2006. I’m not sure what that means. While it was active, the news section had potential with listings both by date and by topic. The links span a wide range of topics, from 2-D gel databases to a repository of digital information for proteomics. While myProteome.com is not as solid as the Mass Spectrometry Blog, it does have its bright spots. Let’s hope it is not about to be canned.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »